Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy.

Mario Giuliano(Regione Campania), Massimo Cristofanilli(Cornell University), Lin-Kang Hsu, Antonio Giordano(University of Siena), R. H. Alvarez, V. Valero, Naoto T. Ueno(Breast Cancer Care), Eleni Andreopoulou(Cornell University), Beverly C. Handy(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)

Journal of Clinical Oncology

May 20, 2010

10.1200/jco.2010.28.15_suppl.1033

Cited by 4

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

|Cancer Cell|2004|1.9k

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k